HOGUE GERALD L. 4
4 · POINT Biopharma Global Inc. · Filed Mar 23, 2023
Insider Transaction Report
Form 4
HOGUE GERALD L.
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-03-21−17,936→ 17,936 totalExercise: $6.97Exp: 2026-12-01→ Common Stock (17,936 underlying) - Exercise/Conversion
Common Stock
2023-03-21$6.97/sh+17,936$125,014→ 21,596 total
Footnotes (1)
- [F1]As previously reported in a Form 4 filed with the Securities and Exchange Commission on June 30, 2021, the reporting person received an option to purchase 35,872 shares of the issuer's common stock (the "Option"). The Option vested 25% on December 1, 2021 and 25% on December 1, 2022, and will vest 25% on December 1, 2023 and 25% on December 1, 2024.